Core Insights - Kura Oncology and Kyowa Kirin announced that results from the KOMET-007 trial of ziftomenib will be presented at the ASH 2025 Annual Meeting on December 8, 2025 [1][2] Group 1: Trial Details - KOMET-007 is a Phase 1a/b study assessing ziftomenib in combination with standard chemotherapies for adults with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML) [2] - The upcoming presentations will include data on newly diagnosed adults with NPM1-m AML and updated results for relapsed or refractory cases treated with ziftomenib combined with venetoclax and azacitidine [2][3] Group 2: Presentation Information - Two oral presentations will take place on December 8, 2025, focusing on the safety and clinical activity results from the KOMET-007 trial [5] - The presentations will provide more mature data, including additional response-evaluable patients and expanded safety summaries [3] Group 3: Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline targeting hematologic malignancies and solid tumors [6] - Ziftomenib is a menin inhibitor aimed at specific genetic drivers of acute myeloid leukemias, with ongoing efforts to advance menin inhibition in various cancer types [6]

Core Insights - Bleximenib, an investigational selective menin inhibitor, demonstrates potential as a combination therapy for relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed, intensive chemotherapy-ineligible AML [1][2] - The Phase 1b study shows promising efficacy and safety data, with an overall response rate (ORR) of 82% for relapsed or refractory AML and 90% for newly diagnosed patients [2][3] - The safety profile indicates a low rate of differentiation syndrome and no significant cardiac safety signals, supporting further investigation in Phase 2 and 3 studies [1][2][3] Company Overview - Johnson & Johnson is committed to addressing unmet medical needs in hematologic malignancies, focusing on innovative treatment options for AML [2][8] - The company is exploring the potential of bleximenib both as a monotherapy and in combination with standard care regimens in ongoing clinical trials [6][8] Industry Context - Acute myeloid leukemia is the most common type of acute leukemia in adults, characterized by low survival rates and poor patient outcomes, particularly in those with KMT2A gene rearrangements and NPM1 mutations [2][7] - The five-year survival rate for AML remains the lowest among leukemias, highlighting the urgent need for effective treatment options [7]